Duccio Baldari, MD
Cardiovascular Disease · Wellington, FLNPI 1992786503
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,104 of the $156,649 with a category attached, or 76.7%. Johnson & Johnson accounts for 82.7% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2019 at $34,438 and has fallen 89.3% since, to $3,682 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,437 payments — averaging $109.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$130K
- Novo Nordisk$5K
- Boehringer Ingelheim International GmbH$3K
- Amgen$2K
- Boehringer Ingelheim$2K
- Novartis$2K
- plus $13K from 47 others
Across 200 payments — averaging $16,734 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.3M
- American Regent$917K
- CSL Behring$703K
- Eisai Inc.$257K
- Amgen$55K
- Boehringer Ingelheim Pharma GmbH & Co.kg$39K
- plus $91K from 5 others
What the payments were for
- Consulting fees$7,9105%
- Speaking & faculty fees$120,10477%
- Travel & lodging$2,4432%
- Food & beverage$25,93817%
- Education$2540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$125,484
- Ozempic$4,650
- JARDIANCE$3,062
- Repatha$727
- Integrity$547
- Barostim Neo System$449
- CAMZYOS$309
- Resolute$228
- Watchman$224
- Impella$215
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$163
- MitraClip$152
- OPTIMIZER SMART SYSTEM$140
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$135
- Cleerly Ischemia$135
- Cleerly Labs$135
- NEXLIZET$125
- NEXLETOL$125
- Kerendia$125
- Wegovy$124
How this compares
$156,649 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 544 | $624,314 |
| EliquisApixaban | 395 | $454,964 |
| EntrestoSacubitril/Valsartan | 297 | $433,993 |
| Repatha SureclickEvolocumab | 288 | $204,784 |
| JardianceEmpagliflozin | 101 | $140,613 |
| Repatha SyringeEvolocumab | 39 | $32,929 |
| FarxigaDapagliflozin Propanediol | 21 | $31,241 |
| VerquvoVericiguat | 13 | $16,608 |
| BrilintaTicagrelor | 19 | $12,873 |
| Praluent PenAlirocumab | 24 | $12,015 |
| OzempicSemaglutide | 13 | $11,743 |
| Metoprolol Succinate | 458 | $5,594 |
| Labetalol Hcl | 142 | $5,274 |
| Rosuvastatin Calcium | 422 | $4,779 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $4,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $129,524 | $624,314544 claims |
| PfizerEliquis | $537 | $454,964395 claims |
| NovartisEntresto | $2,124 | $433,993297 claims |
| Boehringer IngelheimJardiance | $2,135 | $140,613101 claims |
| AstraZenecaFarxiga, Brilinta | $378 | $44,11440 claims |
| MerckVerquvo | $463 | $16,60813 claims |
| Novo NordiskOzempic | $4,994 | $11,74313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Wellington
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.